This activity provides a detailed overview of topiramate, a second-generation antiepileptic drug approved by the FDA in 1996. Topiramate is indicated for the management of epilepsy and migraines and is also approved for chronic weight management in individuals with a body mass index greater than 30 kg/m2. This discussion focuses on the pharmacology of topiramate, including its mechanism of action, dosing guidelines, pharmacokinetics, significant drug interactions, clinical toxicology, and monitoring requirements. Additionally, this session covers adverse events associated with topiramate, highlighting key considerations for interprofessional teams involved in the care of patients with epilepsy, migraine, and related conditions.
Copyright © 2025, StatPearls Publishing LLC.